Several studies have showed that mutations in genes that activate the Ras/Raf/Mek/Erk pathway (NRAS, KRAS, FLT3, and PTPN11) are encountered in relapsed ALL and seem to respond to the MEK inhibitor selumetinib (Figure 1). Here, MAP2K7 is linked to acute lymphoblastic leukemia.